Market Challenges And Opportunities

Glycosylated Peptide Market – Driver

New product launches by the key manufacturers are fueling growth of the glycosylated peptide market. For instance, in 2017, Pfizer Inc., received the U.S. Food and Drug Administration (FDA) approval for Ixifi (infliximab-qbtx), a chimeric human-murine monoclonal antibody, as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Furthermore, in Feb 2017, CT-P10 received approval from the European Commission and in June 2017, it was approved by U.S. FDA. Furthermore, Sumsung Bioepis’s Infliximab biosimilar candidate SB2 got Ministry of Food and Drug Safety approval for Korea in 2016, European Commission approval for Europe in 2016, Therapeutic Goods Administration (TGA) approval for Australia in 2016, US FDA approval in 2017 and Health Canada (HC) approval of Canada in 2017. Moreover, company received European Commission (EC), Ministry of Food and Drug Safety (MFDS) and TGA approval for its Adalimumab biosimilar, SB5 in 2017 and 2018. However, challenges associated with the biosimilar product approval and stringent regulatory policies are restraining growth of the glycosylated peptide market.

Moreover, market players involved in the glycosylated peptide market are adopting strategies such as merger and acquisition for expanding geographical coverage or product portfolio. For instance, in 2014, Bachem AG, a peptide manufacturer and GlyTech Inc., a glycosylated drug developer, entered into co-promotional agreement for GlyTech’s glycosylation technology. The agreement will leverage Bachem by enhancing its sales and marketing resources and GlyTech to promote Bachem for manufacturing of its glycopeptides and glycoproteins. Moreover, in 2016, Teva Pharmaceutical Industries, Israel-based global pharmaceutical company, entered into commercial partnership with Celltrion Inc., a Korean based Biopharmaceutical company to commercialize two of Celltrion’s monoclonal antibody (mAb) biosimilar, CT-P10 (mAb biosimilar to Rituximab) candidates in the U.S. and Canada. The commercial partnership with Celltrion will enable Teva to strengthen its position in biosimilar products and Celltrion to expand its product to global market.